How should Amphotericin B be dosed, formulated, and monitored for serious systemic fungal infections, particularly in patients with renal impairment?

Amphotericin B Dosing, Formulation, and Monitoring

For serious systemic fungal infections, liposomal amphotericin B (L-AmB) at 3-5 mg/kg/day is the preferred formulation due to superior safety and equivalent efficacy compared to conventional amphotericin B deoxycholate, with the lipid formulation being particularly critical in patients with renal impairment or those at high risk for nephrotoxicity. 1, 2, 3

Formulation Selection

First-Line: Lipid Formulations

• Liposomal amphotericin B (L-AmB): 3-5 mg/kg/day for most infections; 10 mg/kg/day for CNS involvement 4, 2

  • Achieves highest peak plasma levels among lipid formulations
  • Lowest rates of infusion-related reactions
  • Preferred in renal impairment 5, 6

• Amphotericin B lipid complex (ABLC): 5 mg/kg/day 2, 3

  • Higher lung tissue concentrations than other formulations
  • May be preferred for pulmonary infections
  • More cost-effective than L-AmB in some settings 1

Alternative: Conventional Amphotericin B Deoxycholate

Reserve amphotericin B deoxycholate exclusively for resource-limited settings where lipid formulations are unavailable 3, 5. When used:

• Dosing: 0.5-1.0 mg/kg/day (maximum 1.5 mg/kg/day) 7, 5
• Infusion: Administer over 2-6 hours in 5% dextrose at 0.1 mg/mL concentration 5
• Initiation strategy:
  • Stable patients with good renal function: Start 0.25 mg/kg/day 5
  • Severe/rapidly progressive infection: Start 0.3 mg/kg/day 5
  • Impaired renal function: Start 5-10 mg, increase gradually by 5-10 mg/day 5

Specific Infection Dosing

Candidiasis

• Candidemia/invasive disease: AmB deoxycholate 0.5-1.5 mg/kg/day 8, 7
• Fluconazole-resistant species (C. glabrata, C. krusei): AmB deoxycholate 0.3-0.6 mg/kg/day for 1-7 days 8
• Duration: Minimum 2-3 weeks after last positive blood culture and symptom resolution 7

Mucormycosis

• Primary therapy: L-AmB 5 mg/kg/day (10 mg/kg/day for CNS involvement) for 4-6 weeks 4, 2
• Alternative: AmB deoxycholate 1.0-1.5 mg/kg/day 4
• Maintenance: Continue 3-6 months until clinical resolution 4

Histoplasmosis

• Severe/disseminated: L-AmB demonstrated 88% response rate vs 64% with deoxycholate, with lower mortality (2% vs 13%) 1
• Switch to oral itraconazole after clinical stabilization 1

Aspergillosis

• L-AmB or ABLC when voriconazole contraindicated 3
• Total cumulative dose up to 3.6 g reported 5

Renal Impairment Management

Dosing Adjustments

• Lipid formulations: No dose adjustment required; preferred in renal dysfunction 5, 6, 9
• Deoxycholate with renal toxicity: Reduce dose by 50% or switch to alternate-day dosing 3, 5
• Hemodialysis patients: 0.5-1.0 mg/kg three times weekly during dialysis sessions 10

Nephrotoxicity Prevention

• Saline loading: Administer 1 L normal saline before and after infusion 4, 7, 5
• Avoid rapid infusion: Infusion rate should not exceed 0.08 mg/kg/hour for deoxycholate 4
• Monitor concomitant nephrotoxins: Avoid aminoglycosides, cyclosporine, pentamidine when possible 5

Monitoring Requirements

Baseline Assessment

• Serum creatinine and BUN
• Electrolytes (potassium, magnesium)
• Complete blood count
• Liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
• Baseline vital signs 5

During Therapy

• Renal function: Monitor creatinine at minimum weekly; more frequently if rising 5
• Electrolytes: Check potassium and magnesium at least weekly; supplement as needed 5
  • Target potassium >3.5 mEq/L
  • Target magnesium >1.5 mg/dL
• Liver enzymes: Check at 1,2, and 4 weeks, then every 3 months 1
• CBC: Monitor for anemia, leukopenia, thrombocytopenia 5
• Vital signs: Record temperature, pulse, respiration, blood pressure every 30 minutes for 2-4 hours after first dose 5

Infusion-Related Reaction Management

Prevention

• Premedication (administer 30-60 minutes before infusion):
  • Acetaminophen 650 mg PO
  • Diphenhydramine 25-50 mg IV/PO 4, 7, 5
  • Consider hydrocortisone 25-50 mg IV for severe reactions 11, 12

Acute Reactions

• Timing: Typically occur 1-3 hours after infusion starts; decrease with subsequent doses 7, 5
• Management: Temporarily interrupt infusion, administer diphenhydramine IV; reactions usually resolve within 1 hour 7
• L-AmB advantage: Significantly fewer infusion reactions than deoxycholate or ABLC 6, 13

Critical Pitfalls to Avoid

1. Never exceed 1.5 mg/kg/day total dose of amphotericin B deoxycholate—risk of fatal cardiac arrest 5
2. Do not use rapid infusion: Associated with hypotension, arrhythmias, shock 5
3. Avoid bacteriostatic water for reconstitution: Use only sterile water for injection 5
4. Do not mix with saline: Amphotericin B precipitates in saline; use only 5% dextrose 5
5. Check dextrose pH: Must be >4.2; add buffer if below this threshold 5
6. Do not delay therapy for diagnosis: In immunocompromised patients with suspected invasive fungal infection, start treatment immediately while pursuing diagnostic workup 2
7. Separate from leukocyte transfusions: Acute pulmonary toxicity reported; separate infusions temporally 5

Treatment Interruption

If therapy interrupted >7 days, restart at lowest dose (0.25 mg/kg) and gradually escalate to avoid severe reactions 5.